Abstract Background. Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor
receptor (EGFR) have been evaluated in patients with metastatic and advanced non-small …

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths. In
the last decade, the epidermal growth factor receptor (EGFR) signalling pathway has …

Abstract Objective The phase III IUNO trial assessed the benefit of maintenance erlotinib
versus erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) …

The study's goal is to evaluate the effectiveness of erlotinib in patients with EGFR mutant
metastatic non-small cell lung cancer (mNSCLC). The patient's medical data were analyzed …

Purpose To evaluate the relationship between treatment efficacy and exposure of total and
unbound erlotinib in patients with non-small cell lung cancer (NSCLC) harboring epidermal …

Background Primary lung cancer is the most common male cancer and is the leading cause
of cancer death in the world. The prognosis is poor despite actual progress of therapy (the …

Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have
shown antitumor efficacy and prolonged progression-free survival (PFS) in patients with non …

The EGFR mutation was the first mutation to be targeted by novel agents, the tyrosine kinase
inhibitors (TKIs). Its occurrence varies by ethnicity; ranging from around 16% in Caucasian …

8105 Background: The majority of NSCLC patients (pts) with activating epidermal growth
factor receptor (EGFR) mutations respond to gefitinib, however acquired resistance to this …

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related deaths. In the
last decade the EGF receptor (EGFR) signaling pathway has emerged as one of the most …